154 related articles for article (PubMed ID: 33531169)
1. The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses.
Shallis RM; Pollyea DA; Zeidan AM
Blood Rev; 2021 Jul; 48():100806. PubMed ID: 33531169
[TBL] [Abstract][Full Text] [Related]
2. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
[TBL] [Abstract][Full Text] [Related]
3. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of platelet recovery degree before and after achieving minimal residual disease negative complete remission in acute myeloid leukemia patients.
Wang Y; Wang H; Wang W; Liu W; Liu N; Liu S; Lu Y
BMC Cancer; 2020 Aug; 20(1):732. PubMed ID: 32758189
[TBL] [Abstract][Full Text] [Related]
5. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.
Walter RB; Gooley TA; Wood BL; Milano F; Fang M; Sorror ML; Estey EH; Salter AI; Lansverk E; Chien JW; Gopal AK; Appelbaum FR; Pagel JM
J Clin Oncol; 2011 Mar; 29(9):1190-7. PubMed ID: 21282535
[TBL] [Abstract][Full Text] [Related]
6. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
Ravandi F; Jorgensen J; Borthakur G; Jabbour E; Kadia T; Pierce S; Brandt M; Wang S; Konoplev S; Wang X; Huang X; Daver N; DiNardo C; Andreeff M; Konopleva M; Estrov Z; Garcia-Manero G; Cortes J; Kantarjian H
Cancer; 2017 Feb; 123(3):426-435. PubMed ID: 27657543
[TBL] [Abstract][Full Text] [Related]
7. Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission.
Shallis RM; Podoltsev NA
Curr Opin Hematol; 2021 Mar; 28(2):110-121. PubMed ID: 33394722
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease in acute myeloid leukemia: coming of age.
Paietta E
Hematology Am Soc Hematol Educ Program; 2012; 2012():35-42. PubMed ID: 23233558
[TBL] [Abstract][Full Text] [Related]
9. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
10. Complete Remission with Incomplete Blood Count Recovery Is a Strong Predictor of Nonrelapse Mortality in Acute Myeloid Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.
Danylesko I; Canaani J; Shimoni A; Fein J; Shem-Tov N; Yerushalmi R; Shouval R; Nagler A
Acta Haematol; 2021; 144(6):613-619. PubMed ID: 34102632
[TBL] [Abstract][Full Text] [Related]
11. Interest of cytogenetic and FISH evaluation for prognosis evaluation in 198 patients with acute myeloid leukemia in first complete remission in a single institution.
Hirsch P; Labopin M; Viguié F; Perot C; Isnard F; Mamez AC; Bilhou-Nabera C; Marzac C; Delhommeau F; Lapusan S; Marie JP; Mohty M; Legrand O
Leuk Res; 2014 Aug; 38(8):907-12. PubMed ID: 24957411
[TBL] [Abstract][Full Text] [Related]
12. Impact of Blood Count Recovery-based Complete Remission Before Allogeneic Hematopoietic Stem Cell Transplantation on Survival in Patients With Acute Myeloid Leukemia.
Ciftciler R; Demiroglu H; Buyukasık Y; Aksu S; Goker H
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):e205-e212. PubMed ID: 30665867
[TBL] [Abstract][Full Text] [Related]
13. How Precision Medicine Is Changing Acute Myeloid Leukemia Therapy.
Heuser M; Mina A; Stein EM; Altman JK
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():411-420. PubMed ID: 31099617
[TBL] [Abstract][Full Text] [Related]
14. Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy.
Schwind S; Jentzsch M; Bach E; Stasik S; Thiede C; Platzbecker U
Curr Treat Options Oncol; 2020 Jan; 21(1):8. PubMed ID: 32002673
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML.
Short NJ; Rafei H; Daver N; Hwang H; Ning J; Jorgensen JL; Kadia TM; DiNardo CD; Wang SA; Jabbour E; Popat U; Oran B; Cortes J; Konopleva M; Yilmaz M; Issa GC; Kantarjian H; Ravandi F
Blood Adv; 2020 Dec; 4(24):6117-6126. PubMed ID: 33351107
[TBL] [Abstract][Full Text] [Related]
16. Using minimal (measurable) residual disease assessments to guide decision-making for timing of allogeneic transplantation in acute myeloid leukemia.
Fasan O
Curr Opin Hematol; 2019 Nov; 26(6):413-420. PubMed ID: 31503019
[TBL] [Abstract][Full Text] [Related]
17. Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia.
Roug AS; Ommen HB
Curr Treat Options Oncol; 2019 Mar; 20(4):28. PubMed ID: 30874904
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic significance of blood count at the time of achieving morphologic leukemia-free state in adults with acute myeloid leukemia].
Ren X; Zhao T; Wang J; Zhu HH; Jiang H; Jia JS; Yang SM; Jiang B; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):185-191. PubMed ID: 28395440
[No Abstract] [Full Text] [Related]
19. A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
Vives S; Martínez-Cuadrón D; Bergua Burgues J; Algarra L; Tormo M; Martínez-Sánchez MP; Serrano J; Herrera P; Ramos F; Salamero O; Lavilla E; López-Lorenzo JL; Gil C; Vidriales B; Falantes JF; Serrano A; Labrador J; Sayas MJ; Foncillas MÁ; Amador Barciela ML; Olave MT; Colorado M; Gascón A; Fernández MÁ; Simiele A; Pérez-Encinas MM; Rodríguez-Veiga R; García O; Martínez-López J; Barragán E; Paiva B; Sanz MÁ; Montesinos P;
Cancer; 2021 Jun; 127(12):2003-2014. PubMed ID: 33626197
[TBL] [Abstract][Full Text] [Related]
20. Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies.
Gaut D; Mead M
Leuk Lymphoma; 2021 Jan; 62(1):8-31. PubMed ID: 33138674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
